EGFR Inhibitors, MHC Expression and Immune Responses : Can EGFR Inhibitors Be Used as Immune Response Modifiers?

OncoImmunology- United States

doi 10.4161/onci.1.1.18073

Full Text

Abstract

Available in

Categories

Date

January 1, 2012

Authors

Brian P. Pollack

Publisher

Informa UK Limited

Related search

597 EGFR Monoclonal Antibodies and EGFR Tyrosine Kinase Inhibitors Have Distinct Effects on the Keratinocyte Innate Immune Response

Journal of Investigative Dermatology

Molecular Biology

English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

Respiratory Medicine

English

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors

Clinical Cancer Research

Cancer Research

English

Tumors Resistant to EGFR Inhibitors Can Arise via Different Mechanisms

Cancer Discovery

English

Integration of EGFR Inhibitors With Radiochemotherapy

Nature Reviews Cancer

Cancer Research

English

Hitting the Target: Measuring EGFR Response to Tyrosine Kinase Inhibitors

Cancer Biology and Therapy

Cancer Research

Molecular Medicine

English

Immune Checkpoint Inhibitors and irAEs

Trends in Immunotherapy

English

EGFR Inhibitors in Treatment of Lung Adenocarcinoma

Research in Oncology

English

QSAR Based Model for Discriminating EGFR Inhibitors and Non-Inhibitors Using Random Forest

Molecular Biology

Applied Mathematics

Biological Sciences

English